Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $43.65 million versus the consensus estimate of $49.47 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.